News

Investigators found significant changes in use of Alzheimer disease drug use, use of non-Alzheimer drug use, and counseling strategies among patients subsequent to amyloid PET.

Complete Response Letter calls for root cause analysis and data from planed registration batches.

The Complete Response Letter highlights issues in the Chemistry, Manufacturing, and Controls section of the application.

A new assessment of audio-recorded conversations show that patients' beliefs, values, and preferences are not consistently represented by surrogates and care providers.

Retrospective study assesses real-world outcomes of treating patients with chronic DME with Iluvien implant.

A new study finds it is safe for patients who undergo heart stent procedures to quit taking aspirin at 3 months so long as they continue taking a P2Y12 inhibitor.

The LAMA/LABA combination therapy was shown to reduce one-year exacerbation rates while not increasing patient risk of cardiovascular events.

Mavenclad will be marketed as a short-term oral drug option for relapsing-remitting multiple sclerosis, but it also carries malignancy risks.

Originally approved in 2002, tegaserod (Zelnorm) was withdrawn in 2007 due to potential safety concerns.

The study will focus on a dozen-plus children with severe asthma over a period of 4 weeks.

As Americans population ages, yet becomes more health conscious, has the average patient suffering from Afib changed in recent years?

How and when do you decide whether to prescribe a patient GLP1 agonists or SGLT2 inhibitors?

How has technology changed the way orthopedic specialists practice and what is driving advances such as minimally invasive spine surgery?

What are some of the future risks, in terms of cardiovascular health, facing the average patient?

Insight regarding the recent change to aspirin guidelines and what it means for patients from platelet specialist Jeffrey Berger, MD.

About 1000 people in the United States have RPE65 gene mutations and inherited retinal diseases.

Before the new treatment-resistant depression therapy reaches the market, Iosifescu anticipates its benefits and limitations in real-world patients.

The oral tablet generics approvals also come with 2 approved shared system REMS programs for ambrisentan.

Barbhaiya talks about what he considers to be misleading success rates for Afib ablation being published in studies.

How has the obesity epidemic in the US affect how orthopedic surgeons approach pre- and post-procedure care?

Discussing the implications and future of wearable technology after the release of the Apple Heart Study.

A new cohort shows that though most physicians stay in medicine after receiving multiple paid malpractice claims, they often end up working in a more isolated setting.

New research shows the public increasingly sees e-cigarettes as equally unhealthy compared to cigarettes—but that’s not the whole picture.

The application to the FDA for icosapent ethyl seeks a new indication to reduce the risk of major adverse cardiovascular events.

What sort of problems will orthopedic surgeons face in the future and how has the average patient changed in recent years?

MD Magazine sat down with Chirag Barbhaiya, MD, of NYU Langone Health, to discuss the updated guidelines for treating a patient with Afib.

The American Academy of Pediatrics says the nasal spray is an acceptable option for influenza vaccination in the coming flu season.

A fourth phase 3 study of investigational drug SPN-812 demonstrated a significant decrease in ADHD-RS-5 scores compared to placebo.